ViCentra Presents Large-Scale Real-World Evidence Demonstrating Kaleido Insulin Patch Pump System Delivers Stable Glucose Control with Very Low Hypoglycemia
- Analysis of 3,918 adults across Germany, the Netherlands and France, with no eligibility criteria beyond active system use, covering 323,814 person-days of real-world experience
- Users achieved median time in range of2%, while median time below 54 mg/dL (3.0 mmol/L) was 0.21% – equivalent to approximately three minutes per day
- Median coefficient of variation of 28.7%, well below the 36% stability threshold and consistent across every adult age group
Utrecht, the Netherlands — October 1, 2026
ViCentra, a European medical device company commercializing the Kaleido insulin patch pump system, today announced new real-world data showing strong glycemic outcomes in 3,918 adults with type 1 diabetes using the Kaleido insulin patch pump with Diabeloop’s DBLG1 automated insulin delivery algorithm and the Dexcom G6 continuous glucose monitoring system.
